DiaMedica Therapeutics Inc. (DMAC) vs Ovid Therapeutics Inc. (OVID)
A side-by-side comparison of DiaMedica Therapeutics Inc. and Ovid Therapeutics Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
DMAC
DiaMedica Therapeutics Inc.
$8.19HealthcareDelayed quote: Oct 6, 2026, 3:35 PM EDT
OVID
Ovid Therapeutics Inc.
$2.40HealthcareDelayed quote: Oct 6, 2026, 3:30 PM EDT
Total return — DMAC vs OVID
growth of $100 · dividends reinvested · last 9yDMAC +58.3% (+5.2%/yr)OVID -80.9% (-16.8%/yr)DMAC compounded faster over this window
Log scale — wide-divergence pair
DMAC OVID
DMAC vs OVID: by the numbers
- •OVID is the larger company ($447M vs $441M market cap).
- •Both run net losses; DMAC's is the smaller (0.00% vs -2178.90% net margin).
Metrics side by side
Valuation
| Metric | DMAC | OVID |
|---|---|---|
| P/S ratio | N/A | 282.38 |
| P/B ratio | 11.51 | 2.13 |
Profitability
| Metric | DMAC | OVID |
|---|---|---|
| Gross margin | 0.00% | 100.00% |
| Operating margin | 0.00% | -585.20% |
| Net margin | 0.00% | -2178.90% |
| ROE | -97.92% | -16.43% |
| ROIC | -100.87% | -26.29% |
Growth (annualized)
| Metric | DMAC | OVID |
|---|---|---|
| Revenue CAGR (5Y) | N/A | -62.76% |
| Total return CAGR (5Y) | 16.41% | -6.98% |
Frequently asked
- How have DMAC and OVID total returns compared?
- Over the past 5 years, DMAC delivered 16.41% and OVID delivered -6.98% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.